Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke

Launched by CAPITAL MEDICAL UNIVERSITY · Apr 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different fluids used for hydration in patients who have had a severe type of stroke called hemorrhagic stroke. The trial compares normal saline, which has a high level of chloride and can lead to high chloride levels in the blood (called hyperchloremia), with a fluid called Multiple Electrolytes Injection II, which is thought to be a better choice because its composition is closer to what our bodies naturally have. The goal is to find out which fluid helps patients better in critical care settings.

To participate in this trial, patients must be over 18 years old and diagnosed with a hemorrhagic stroke confirmed by a CT or MRI scan. They also need to require fluid therapy to help with their recovery. However, those who have had their stroke for more than 72 hours, have certain health conditions, or are pregnant cannot participate. If eligible, participants will receive one of the two fluids being studied and will be monitored closely to see how it affects their health. This trial is not yet recruiting, so if you are interested or know someone who might be, it's best to keep an eye out for updates on when it will start.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a diagnosis of hemorrhagic stroke (cerebral hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage confirmed by CT or MRI, except for subdural or extradural hemorrhage caused by tramma)
• • Patients requiring fluid therapy
• • Patients over 18 years old
• Exclusion Criteria:
• • Hemorrhage onset more than 72hours
• • Preexisting hyperchloremia(blood chloride \> 110mmol/L)
• • Presence of hypothalamic disease or cerebral salt wasting syndrome
• • Patients who can eat by themselves
• • Patients receiving routine RRT
• • Patients with known allergic or adverse reactions to the liquid used
• • Patients with organ failure (such as heart failure, renal failure, liver failure) or end-stage disease
• • Patients with autoimmune diseases, inflammatory diseases, metabolic diseases and blood diseases
• • Patients with serious heart disease or arrhythmia
• • Patients who are expected to have difficulty complying with the study plan or collecting data completely
• • Pregnant or lactating women
• • No informed consent was signed
• • Patients participating in other clinical trials
• • Other conditions deemed by the investigator to be ineligible for participation in the study